Allovir Inc reports results for the quarter ended in January - Earnings Summary

Kalaris Therapeutics

15/05/2024 08:39

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss
of 26
cents​​ per share for the quarter ended in January, higher than
the same quarter last year, when the company reported EPS of -44
cents.  The mean expectation of four analysts for the quarter
was for a loss of 16 cents per share. Wall Street expected
results to range from -19 cents to -13 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Allovir Inc's reported EPS for the quarter was a loss
of 26
cents​.
    * The company reported a quarterly loss of $30.3 million.
    * Allovir Inc shares had risen by 2.3% this quarter and
gained 13.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 14.5%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 3 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "sell"

Wall Street's median 12-month price target for Allovir Inc is
$1.00 
This summary was machine generated from LSEG data May 15 at
07:39 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.16          -0.26          Missed
 Dec. 31 2023      -0.43          -0.36          Beat
 Sep. 30 2023      -0.42          -0.39          Beat
 Jun. 30 2023      -0.45          -0.48          Missed